Abstract
Coronary artery disease is the major cause of mortalilty in the West with coronary artery bypass surgery (CABG) being a means of restoring blood supply to ischaemic myocardium. The long saphenous vein is the most commonly used bypass conduit but its patency is inferior to the internal thoracic artery, the ‘gold standard’ graft. In conventional procedures the saphenous vein is harvested in such a manner that considerable vascular damage is inflicted. The structures mainly affected by this vascular trauma are the endothelium, autonomic nerves and vascular smooth muscle all containing cells with the potential to release nitric oxide (NO). While the majority of studies into the potential role of NO in vein graft performance have focussed on the involvement of endothelial nitric oxide synthase (eNOS) less information is available regarding the role of the inducible isoform of nitric oxide synthase (iNOS). While the effects of eNOS-derived NO are principally beneficial, iNOS is generally associated with pathological conditions. While potential pathophysiological roles of iNOS are discussed in this review we also outline many studies suggesting that this isoenzyme plays an important role in maintaing vein graft patency in patients undergoing CABG, particularly when the saphenous vein is harvested with minimal surgical trauma.
Keywords: Human saphenous vein, bypass graft, iNOS, nitric oxide, coronary artery disease.
Current Vascular Pharmacology
Title:Inducible Nitric Oxide Synthase and Vein Graft Performance in Patients Undergoing Coronary Artery Bypass Surgery: Physiological or Pathophysiological Role?
Volume: 12 Issue: 1
Author(s): Michael R. Dashwood and Andrzej Loesch
Affiliation:
Keywords: Human saphenous vein, bypass graft, iNOS, nitric oxide, coronary artery disease.
Abstract: Coronary artery disease is the major cause of mortalilty in the West with coronary artery bypass surgery (CABG) being a means of restoring blood supply to ischaemic myocardium. The long saphenous vein is the most commonly used bypass conduit but its patency is inferior to the internal thoracic artery, the ‘gold standard’ graft. In conventional procedures the saphenous vein is harvested in such a manner that considerable vascular damage is inflicted. The structures mainly affected by this vascular trauma are the endothelium, autonomic nerves and vascular smooth muscle all containing cells with the potential to release nitric oxide (NO). While the majority of studies into the potential role of NO in vein graft performance have focussed on the involvement of endothelial nitric oxide synthase (eNOS) less information is available regarding the role of the inducible isoform of nitric oxide synthase (iNOS). While the effects of eNOS-derived NO are principally beneficial, iNOS is generally associated with pathological conditions. While potential pathophysiological roles of iNOS are discussed in this review we also outline many studies suggesting that this isoenzyme plays an important role in maintaing vein graft patency in patients undergoing CABG, particularly when the saphenous vein is harvested with minimal surgical trauma.
Export Options
About this article
Cite this article as:
Dashwood R. Michael and Loesch Andrzej, Inducible Nitric Oxide Synthase and Vein Graft Performance in Patients Undergoing Coronary Artery Bypass Surgery: Physiological or Pathophysiological Role?, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/157016111201140327164409
DOI https://dx.doi.org/10.2174/157016111201140327164409 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comparative Study of Marketing Authorization of Drug Eluting Coronary Stents (DES) in India and Developed Countries (USA & EU)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets Scutellaria barbata: A Review on Chemical Constituents, Pharmacological Activities and Clinical Applications
Current Pharmaceutical Design microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews GCH1, BH4 and Pain
Current Pharmaceutical Biotechnology Preventing Vascular Graft Failure: Endothelial Cell Seeding and Tissue Engineering
Vascular Disease Prevention (Discontinued) To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials The Role of Colchicine in the Prevention of Cerebrovascular Ischemia
Current Pharmaceutical Design Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update
Current Vascular Pharmacology Pain and Inflammation
Current Medicinal Chemistry Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Developing Specific Therapeutic Strategies for Transfusion-Related Acute Lung Injury. An Overview of Potentially Useful Animal Models
Cardiovascular & Hematological Agents in Medicinal Chemistry